Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant omicron is now under investigation. We evaluated cross-neutralizing activity against omicron in coronavirus disease 2019 (COVID-19) convalescent patients (n = 23) who had received 2 doses of an mRNA vaccination (BNT162b2 or mRNA-1273). Intriguingly, after the second vaccination, the neutralizing antibody titers of subjects against SARS-CoV-2 variants, including omicron, all became seropositive, and significant fold-increases (21.1-52.0) were seen regardless of the disease severity. Our findings thus demonstrate that 2 doses of mRNA vaccination to SARS-CoV-2 convalescent patients can induce cross-neutralizing activity against omicron.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129189 | PMC |
| http://dx.doi.org/10.1093/infdis/jiac178 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlabelled: The evolution of SARS-CoV-2 has resulted in antigenically distinct variants that challenge vaccine-induced immunity. The KP.2 monovalent mRNA vaccine was deployed in 2024 to address immune escape by emerging SARS-CoV-2 subvariants.
View Article and Find Full Text PDFTwo cross-neutralizing antibodies isolated from a COVID-19 convalescent via single B cell sorting.
Arch Virol
August 2025
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University, 310003, Hangzhou, China. yshao@b
The ongoing emergence of Omicron subvariants, which exhibit significant resistance to existing therapeutic antibodies, underscores the urgent need to develop new reagents capable of broadly and effectively neutralizing current subvariants. Antigen-specific memory B cells were sorted by flow cytometry. The heavy and light variable region genes of monoclonal antibodies (mAbs) were amplified and cloned into expression vectors.
View Article and Find Full Text PDFThe clinical efficacy of systemic oncolytic virotherapy (OV) is constrained by the rapid development of neutralizing antibodies (nAbs), which prevent repeat systemic administration, a critical barrier to sustained anti-tumor immunity. Vesiculoviruses offer potent oncolytic and immunogenic potential. However, leveraging their serological diversity for repeat dosing remains unexplored.
View Article and Find Full Text PDFA single residue change only differing by an atomic group can drive imprinting to influenza.
Res Sq
July 2025
Drukier Institute for Children's Health, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
First described as original antigenic sin (OAS), which is deleterious, or now immune imprinting, which also accounts for beneficial effects, it is clear that immune responses to viruses tend to be biased by previous exposure to similar strains. Various non-exclusive models for the basis of imprinting include that it results from unique features of childhood immunity; it is driven by pre-existing serum antibodies via epitope masking; or it occurs as a byproduct of residual memory following viral antigenic evolution. To understand the basis and impact of imprinting from influenza, we characterized the B cell responses of young children upon consecutive first infections with divergent H1N1 and H3N2 influenza viruses.
View Article and Find Full Text PDFNeutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC.
Vaccine
July 2025
Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan; Institute for Vaccine Research and Development, Hokkaido University, Sapporo, Japan. Electronic address:
The emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.
View Article and Find Full Text PDF